AI Drug Discovery Outpaces Lab Validation Capacity, Creating New Market for Verification Tools

Computational drug discovery platforms now generate candidate compounds faster than labs can experimentally validate them. 10x Science, backed by Y Combinator, raised $4.8M to address this bottleneck with AI-native protein characterization tools. The "validation gap" — where computational output exceeds wet-lab throughput — signals infrastructure opportunities beyond full-stack discovery platforms. **Analysis:** This mirrors earlier technology adoption cycles where data generation outpaced processing capacity.